Obese men tend to have lower Prostate Specific Antigen scores, resulting in fewer referrals for biopsies. Consequently, obese men have higher rates of prostate cancer progression. This study recommends that physicians consider a patient’s Body Mass Index when considering a biopsy referral.
Abstract
Background
Previous studies suggest that obesity is associated with higher prostate cancer progression and mortality despite an association with lower prostate cancer incidence. This study aims to better understand these apparently inconsistent relationships among obese men by combining evidence from 3 nationally representative cross-sectional surveys.
Methods
We evaluated relationships between obesity and 1) testosterone concentrations in the Third National Health and Nutrition Examination Survey (NHANES III; n = 845); 2) prostate-specific antigen (PSA) in NHANES 2001-2004 (n = 2458); and 3) prostate biopsy rates in the National Health Interview Survey (NHIS 2000; n = 4789) population. Mean testosterone, PSA concentrations, and biopsy rates were computed for Body Mass Index (BMI) categories.
Results
Testosterone concentrations were inversely associated with obesity (P-trend 35) versus lean (BMI 4 ng/mL (3% vs 8%; P 30 versus 16% with BMI 30 versus BMI
Conclusions
Obesity was associated with lower PSA-driven biopsy rates. These data support further studies to test the hypothesis that obesity affects prostate cancer detection independent of prostate cancer risk by decreasing the PSA-driven biopsy rates.
To read this article in its entirety, please visit our website.
— Niyati Parekh, PhD, RD, Yong Lin, PhD, Robert S. DiPaola, MD, Stephen Marcella, MD, MPH, Grace Lu-Yao, PhD, MPH
This article originally appeared in the September 2010 issue of The American Journal of Medicine.
